American National Bank & Trust’s United Therapeutics UTHR Stock Holding History

American National Bank & Trust’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-73	Closed	-$10K	–	295
2017 Q1	$10K	Hold	73	–	–	﹤0.01%	235
2016 Q4	$10K	Hold	73	–	–	﹤0.01%	231
2016 Q3	$9K	Hold	73	–	–	﹤0.01%	225
2016 Q2	$8K	Sell	73 -139	-66%	-$15.5K	﹤0.01%	228
2016 Q1	$24K	Hold	212	–	–	0.01%	140
2015 Q4	$33K	Sell	212 -101	-32%	-$14.7K	0.01%	135
2015 Q3	$41K	Hold	313	–	–	0.02%	130
2015 Q2	$54K	Sell	313 -153	-33%	-$27.5K	0.02%	124
2015 Q1	$80K	Hold	466	–	–	0.03%	106
2014 Q4	$60K	Sell	466 -46	-9%	-$5.93K	0.02%	127
2014 Q3	$66K	Buy	+512	New	+$52.8K	0.03%	114

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

American National Bank & Trust's UTHR Position: Q2 2017 in Review

American National Bank & Trust sold out of United Therapeutics (UTHR) in Q2 2017, closing a stake of 73 shares — an estimated $10K sold.

American National Bank & Trust first reported a position in UTHR in Q3 2014 and held it in 11 quarters. The position peaked at $80K in Q1 2015. 373 funds tracked by Wall St. Rank hold UTHR as of Q2 2017.

American National Bank & Trust reported no remaining United Therapeutics position as of Q2 2017 after selling out during the quarter.
American National Bank & Trust sold 73 United Therapeutics shares in Q2 2017, an estimated $10K.
American National Bank & Trust first reported a position in United Therapeutics in Q3 2014 and held it in 11 quarters.
American National Bank & Trust's United Therapeutics position peaked at $80K in Q1 2015.
373 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2017.

Based on American National Bank & Trust's 13F filing for Q2 2017, filed 7 Jul 2017.